Primary Breast Cancers are Reduced by Raloxifene
University of Pennsylvania Cancer Center
Last Modified: May 19, 1998
In a second analysis of the study presented yesterday, researchers found that the risk of developing breast cancer was reduced by 58% in women taking Raloxifene, compared to women receiving a placebo. This dramatic reduction was observed in postmenopausal women being treated for osteoporosis who had no history of breast cancer. The researchers conclude that there is substantial evidence for a profound reduction in the risk of developing breast cancer for patients taking Raloxifene.
Raloxifene has target-site specific estrogen agonist effects on bone and lipid an antagonist effects on breast and uterine tissue, via modulation an high affinity binding to the estrogen receptor on tumor cells.